| 2.68 0.04 (1.52%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.58 | 1-year : | 4.18 |
| Resists | First : | 3.06 | Second : | 3.58 |
| Pivot price | 2.68 |
|||
| Supports | First : | 2.41 |
Second : | 2 |
| MAs | MA(5) : | 2.72  |
MA(20) : | 2.59 |
| MA(100) : | 2.54 |
MA(250) : | 9.9 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 39 |
D(3) : | 52.2 |
| RSI | RSI(14): 55.7 |
|||
| 52-week | High : | 22.21 | Low : | 1.9 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ANTX ] has closed above bottom band by 49.4%. Bollinger Bands are 16.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.68 - 2.7 | 2.7 - 2.71 |
| Low: | 2.55 - 2.57 | 2.57 - 2.59 |
| Close: | 2.65 - 2.68 | 2.68 - 2.71 |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Thu, 04 Jul 2024
Is AN2 Therapeutics (NASDAQ:ANTX) In A Good Position To Invest In Growth? - Simply Wall St
Tue, 14 May 2024
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights - Business Wire
Sun, 28 Apr 2024
ANTX Stock Price and Chart — NASDAQ:ANTX - TradingView
Thu, 28 Mar 2024
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights - Yahoo Finance
Wed, 13 Mar 2024
5 Oversold NASDAQ Stocks To Buy Right Now - Insider Monkey
Mon, 12 Feb 2024
AN2 Therapeutics shares fall after pausing lung disease study enrollment - Reuters
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 30 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 25.3 (%) |
| Held by Institutions | 70.5 (%) |
| Shares Short | 677 (K) |
| Shares Short P.Month | 747 (K) |
| EPS | -2.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.71 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42.4 % |
| Return on Equity (ttm) | -68.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -59 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -1.07 |
| PEG Ratio | 0 |
| Price to Book value | 0.72 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|